Cancer | Epigenetic mark | Used for | Reference |
---|---|---|---|
Cancer of unknown primary | DNA methylation | Diagnosis | Moran, Martinez-Cardus et al. 2016 [89] |
Central nervous system tumors | DNA methylation | Diagnosis, subclassification | Capper, Jones et al. 2018 [76] |
Pilocytic astrocytomas | DNA methylation | Diagnosis, subclassification | Lambert, Witt et al. 2013 [77] |
Colorectal cancer | DNA methylation | Diagnosis, subclassification | Bormann, Rodriguez-Paredes et al. 2018 [78] |
Atypical teratoid/ rhabdoid tumors | DNA methylation | Subclassification | Johann, Erkek et al. 2016 [81] |
Juvenile myelomonocytic leukemia | DNA methylation | Subclassification, clinical outcome prediction | Lipka, Witte et al. 2017 [80] |
Cholangiocarcinoma | DNA methylation | Prognosis prediction | Goeppert, Toth et al. 2019 [79] |
Brain tumors | DNA methylation | Disease progression and recurrence risk prediction | Sahm, Schrimpf et al. 2017 [82] |
Brain tumors | DNA methylation | Survival prediction | Wiestler, Capper et al. 2014 [83] |
Bladder cancer | Histone modification | Recurrence risk prediction | Ellinger, Schneider et al. 2016 [86] |
Prostate cancer | Histone modification | Recurrence risk prediction | Seligson, Horvath et al. 2005 [85] |
Esophageal cancer | DNA methylation | Risk prediction | Takeshima and Ushijima 2019 [72] |
Colorectal cancer | Histone modification | Liquid biopsies | Gezer, Yoruker et al. 2015 [90] |
Lung cancer | DNA methylation of cell-free DNA | Liquid biopsies | Liang, Zhao et al. 2019 [92] |